Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment

Agostinetto, Rita

doi:10.1186/1477-7827-7-48

Cited by 9 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2001; Kanitz et al. 2002), and, in human fertility, can be patient‐dependent with factors such as age, parity, and overall ovarian function impacting results (Agostinetto 2009). Supplying a dual‐active gonadotropin may alleviate some of the problems encountered with administering only FSH and allow the desired ratio of FSH/LH to be achieved using one molecule.…”

Section: Recombinant Gonadotropin Productionmentioning

confidence: 99%

Advances in Recombinant Gonadotropin Production for Use in Bovine Superovulation

Hesser

Morris

Gibbons

2011

Reprod Domestic Animals

View full text Add to dashboard Cite

Bovine ovarian hyperstimulation is a process that currently relies on pituitary-derived follicle stimulating hormone (FSH) to facilitate the maturation of multiple follicles to achieve dominance and eventual ovulation. The prevalence of this process, also called superovulation, has more than doubled in the past 10 years, but the efficiency of recovered transferable embryos has remained low at ~6 per collection. The use of pituitary-derived products presents other problems including contamination from other hormones, inconsistencies within and among batches, and the possibility of the spread of disease-transmitting agents. Recombinant gonadotropins have been engineered to yield varieties of FSH and luteinizing hormone from a myriad of heterologous hosts with the resulting products demonstrating various levels of biological activity. Research has also been devoted to alternative delivery methods to reduce the frequency of injections required in current superovulatory protocols. Together, recombinant gonadotropins and alternative delivery approaches potentially provide an economical alternative to the use of pituitary-derived products.

show abstract

Section: Recombinant Gonadotropin Productionmentioning

confidence: 99%

Advances in Recombinant Gonadotropin Production for Use in Bovine Superovulation

Hesser

Morris

Gibbons

2011

Reprod Domestic Animals

View full text Add to dashboard Cite

show abstract

“…14,15 A mixture of follitropin alpha and lutropin alpha (follitropin alpha/lutropin alpha 150 IU/75 IU) has been recently commercially available in a single product called Pergoveris TM (Merck Serono). 16 Biopatency studies have confirmed that the new drug is treated in the body similarly as if each product were administered separately. 14,16 This combination could be of value for the stimulation of follicular development in infertile women with severe endogenous FSH and LH deficiency, using a single daily injection.…”

Section: Introductionmentioning

confidence: 89%

“…16 Biopatency studies have confirmed that the new drug is treated in the body similarly as if each product were administered separately. 14,16 This combination could be of value for the stimulation of follicular development in infertile women with severe endogenous FSH and LH deficiency, using a single daily injection. 17…”

Section: Introductionmentioning

confidence: 89%

Recombinant follitropin alfa/lutropin alfa in fertility treatment

Gibreel

Bhattacharya²

2009

BTT

View full text Add to dashboard Cite

Recombinant human follicle stimulating hormone (rFSH) and luteinizing hormone (LH), also known as follitropin alpha and lutropin alpha, are manufactured by genetic engineering techniques which ensure high quality and batch to batch consistency. Follitropin alpha can be used for controlled ovarian hyperstimulation in assisted reproduction, ovulation induction for WHO group I and II anovulatory infertility and in men with hypogonadotrophic hypogonadism (HH) or idiopathic oligo-asthenospermia. Current evidence suggests superiority of urinary human menopausal gonadotropin (HMG) over follitropin alpha in controlled ovarian hyperstimulation for IVF in terms of live birth rate per couple. Addition of lutropin to follitropin alpha in an unselected IVF population does not appear to confer any benefit; however, it may have a role in ovulation induction in women with hypothalamic hypogonadism. Urinary HMG preparations (especially currently available highly purified preparations) are more cost effective than rFSH in terms of cost per ongoing pregnancy. However, women using rFSH injection pen devices have higher levels of satisfaction as compared to those using urinary HMG by means of conventional syringes.

show abstract

“…Gonadotrophins used for conventional ovulation induction are either urinary or recombinant products. Urinary human menopausal gonadotrophins contain a combination of FSH 75 iu and LH 75 iu, while the recombinant preparations usually contain either FSH or LH activity, although newer preparations with combined recombinant FSH and LH in a single injection are now available . In women with hypothalamic hypogonadism, recombinant FSH alone stimulates follicular growth, but results in inadequate estrogen production, confirming the need for LH to fulfil the ‘two cell, two gonadotrophin’ requirement for ovarian steroidogenesis (Figure ) …”

Section: Who Group I Disorders – Hypothalamic Pituitary Failure (Hypomentioning

confidence: 99%

Current issues in ovulation induction

Gorthi

Balen²,

Tang

2012

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

Key content Anovulation contributes to infertility in up to one‐quarter of couples attending infertility clinics. Polycystic ovary syndrome accounts for almost 90% of cases of anovulatory infertility. Careful monitoring is needed to minimise the complications of ovulation induction treatment such as multiple pregnancy and ovarian hyperstimulation syndrome. Lifestyle has a very significant impact on ovarian function. Learning objectives To be able to identify causes of anovulation. To understand appropriate patient selection and to be able to address lifestyle issues and individualise treatment. To recognise the significance of ovulation and cumulative conception rates. Ethical issues Should fertility treatment be offered to overweight and obese women? Counselling should be made available for couples undergoing fertility treatments, including ovulation induction.

show abstract

Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment

Cited by 9 publications

References 18 publications

Advances in Recombinant Gonadotropin Production for Use in Bovine Superovulation

Advances in Recombinant Gonadotropin Production for Use in Bovine Superovulation

Recombinant follitropin alfa/lutropin alfa in fertility treatment

Current issues in ovulation induction

Contact Info

Product

Resources

About